Abeona Therapeutics (ABEO) announced activation of the newest Qualified Treatment Center for FDA-approved ZEVASKYN gene-modified cellular sheets. This first-of-its-kind therapy, an outcome of a decade of research by Abeona and two decades of research at Stanford Medicine, where the technology originated, will be used to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa. Lucile Packard Children’s Hospital Stanford has completed QTC start-up activities and is now ready to accept patients for treatment with ZEVASKYN.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Positive Outlook for Abeona Therapeutics Amid FDA Challenges and Promising ZEVASKYN Launch
- Fair Isaac, Aeva, Abeona, Cipher, Verisign: Insider Sales Unveiled!
- Abeona Therapeutics Sells Priority Review Voucher for $155M
- Abeona Therapeutics closes sale of Rare Pediatric Disease PRV for $155M
- Abeona Therapeutics announces option exercise by Beacon Therapeutics